Welcome to our dedicated page for Pacific Biosc SEC filings (Ticker: PACB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The PacBio (Pacific Biosciences of California, Inc., NASDAQ: PACB) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports, annual and quarterly reports, and other documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on PacBio’s financial performance, risk factors, and business operations related to its advanced sequencing solutions and integrated genetic analysis platforms.
For a life science technology company like PacBio, investors often look to annual reports on Form 10-K and quarterly reports on Form 10-Q for discussions of revenue from instruments, consumables, and services, as well as commentary on product adoption, research collaborations, and regional trends. Current reports on Form 8-K, such as the November 5, 2025 filing that furnished a press release on third quarter 2025 financial results, provide timely updates on material events and earnings announcements.
Stock Titan enhances these SEC filings with AI-powered summaries designed to explain key sections in clear language. Instead of reading full-length documents unaided, users can rely on AI-generated highlights to understand topics such as PacBio’s use of GAAP and non-GAAP financial measures, its description of sequencing platforms and applications, and management’s discussion of business risks and opportunities.
In addition to periodic reports and 8-Ks, investors may also review proxy statements and, where applicable, insider transaction reports on Form 4 to understand equity-related activity by officers and directors. With real-time updates from EDGAR and AI-assisted insights, this PACB filings page helps users quickly locate and interpret the regulatory information that PacBio provides about its operations in genomic sequencing and analytical laboratory instruments.
Pacific Biosciences of California, Inc. reported that officer Michele Farmer received new equity awards. On February 27, 2026, Farmer was granted a stock option covering 179,670 shares of common stock at an exercise price of $0.00 per share, and an award of 89,835 shares of common stock at $0.00 per share.
The 89,835-share award is in the form of Restricted Stock Units that vest in three equal annual installments on February 15, 2027, 2028, and 2029, if Farmer continues as a service provider. The option vests in 36 equal monthly installments beginning March 27, 2026, also conditioned on continued service.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported that executive James R. Gibson II received new equity awards. He was granted a stock option for 667,696 shares with an exercise price of $0.00 per share, and 333,848 shares of common stock as restricted stock units.
The RSUs will vest in equal annual installments on February 15 of 2027, 2028, and 2029, subject to his continued service. The stock option will vest in 36 equal monthly installments beginning on March 27, 2026, also conditioned on continued service. These are non-cash, compensation-related acquisitions rather than open-market purchases.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported that company officer Mark Van Oene acquired new equity awards. He received a stock option for 1,000,000 shares at an exercise price of $0.00 per share and a grant of 500,000 shares of common stock.
The 500,000 shares are in the form of Restricted Stock Units that vest in three equal annual installments on February 15, 2027, 2028, and 2029, contingent on continued service. The 1,000,000-share option vests in 36 equal monthly installments beginning on March 27, 2026, also subject to his continued status as a service provider.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported that officer Christian O. Henry received equity-based compensation on February 27, 2026. He was granted a stock option for 1,841,621 shares at an exercise price of $0.00 and 920,810 shares of common stock represented by restricted stock units.
The option vests in 36 equal monthly installments beginning on March 27, 2026, while the RSUs vest in three equal annual installments each February 15 of 2027, 2028, and 2029, in both cases requiring his continued service to the company.
Mark Van Oene reported sales of Common stock. The filing lists two transactions: 02/17/2026 sale of 129,790 shares for $204,549.04 and 02/18/2026 sale of 55,107 shares for $89,769.30. The filing also lists Restricted Stock to be sold on 03/02/2026.
Christian Henry reported sales of PACB common stock. The filing shows dispositions of 331,793 shares on 02/17/2026 and 140,874 shares on 02/18/2026, with proceeds listed as $522,905.77 and $229,483.75, respectively.
The transactions are reported on Form 144 and reflect restricted-stock sales by an issuer-side holder; timing and amounts are stated in the filing.
Pacific Biosciences of California, Inc. filed a Form S-3 shelf registration dated February 25, 2026 that permits the company to offer, from time to time, common stock, preferred stock, depositary shares, debt securities, warrants, subscription rights, purchase contracts and units. The filing also covers possible resales by selling stockholders; the company will not receive proceeds from resale transactions by those selling stockholders.
The prospectus describes general terms and distribution methods and states that specific offering amounts, prices, terms and expected net proceeds (when applicable) will be provided in prospectus supplements. The company’s common stock trades on Nasdaq under the symbol PACB.
Pacific Biosciences of California, Inc. files its annual report describing a focused long-read sequencing business, a recent asset sale, and ongoing losses and risks. The company designs and manufactures HiFi long-read platforms such as Revio and Vega, plus SMRT Cells, reagents, and application-specific kits for research markets.
On January 30, 2026, PacBio sold intellectual property and other assets related to its short-read DNA sequencing technology to an Illumina affiliate for a $50.0 million cash purchase price, with approximately $48.1 million in net proceeds after a payment direction to former Apton equity holders. It ended 2025 with $49.2 million in backlog, expects most to convert to 2026 revenue, and continues to invest heavily in R&D while recording sizable intangible impairments and restructuring charges.
The company reports recurring net losses and does not expect profitability in 2026, highlighting expense-reduction plans, significant outstanding convertible notes totaling $641.0 million principal, regulatory and competitive pressures in sequencing, and dependence on key personnel as major risks for its future performance.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. officer Mark Van Oene reported two transactions in the company’s common stock. On February 17, 2026, he sold 129,790 shares in open-market transactions at a weighted average price of $1.576 per share, with individual prices ranging from $1.55 to $1.70. On February 18, 2026, he sold 55,107 shares at a weighted average price of $1.629 per share, with prices ranging from $1.51 to $1.68. The filing states that the reported amount includes shares mandatorily sold to cover tax withholding obligations upon vesting of restricted stock units. After these transactions, he directly owned 1,742,638 shares, which includes 7,500 shares acquired on September 2, 2025 under the company’s 2010 Employee Stock Purchase Plan.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. officer Christian O. Henry reported open-market sales of company common stock. On February 17, he sold 331,793 shares at a weighted average price of $1.576 per share. On February 18, he sold an additional 140,874 shares at a weighted average price of $1.629 per share.
After these transactions, Henry directly held 2,814,374 shares following the February 17 sale and 2,673,500 shares following the February 18 sale, all as common stock. A footnote explains that the reported shares represent stock mandatorily sold to cover tax withholding obligations related to vesting restricted stock units, and that each sale price shown is a weighted average over a disclosed price range.